Docebo heads into its third-quarter report with a very different setup than it had three months ago. Last time, the stock was languishing and sentiment leaned clearly bearish. Since then, management raised its full-year revenue outlook, described a second straight quarter of accelerating underlying ARR, and argued that enterprise demand was finally doing the heavy lifting. The market bought the story: shares have climbed about 46% since that report while the S&P 500 barely moved. The question now is whether the September quarter supplies enough proof to justify a rerating that has already happened.
On the headline numbers, there is little room for surprise built into the revenue line. Consensus sits at $69.6 million, which lands squarely at the midpoint of management's unusually tight $69.5 million to $69.7 million guidance range and would represent growth of roughly 13% from $61.6 million a year ago. That is solid, particularly given that the company is still absorbing roughly $19 million of AWS and Dayforce run-off that suppresses reported growth. For the full year, the Street's $275.2 million sits just below the midpoint of the reaffirmed $274.5 million to $276.5 million range, suggesting analysts have not gotten ahead of the company. The earnings bar looks steeper. GAAP consensus of $0.44 per share compares with $0.30 last quarter and $0.27 a year ago, a sizable step up that leaves less margin for error on costs.
That cost question is where the narrative could get tested. Management held EBITDA guidance flat last quarter even while raising revenue, explaining that a new healthcare pod and a three-person sales team, along with the Forward Deployed Engineer program, would soak up near-term upside. Those FDE costs land in R&D and cost of revenue before they generate a dollar. Management also deferred any explanation of how healthcare and FDE will be monetized until this call. A clear framework, with some sense of pricing and margin profile, would turn two interesting experiments into credible growth vectors. Vague answers would leave investors paying for investments without a payoff map.
On the demand side, the evidence to look for is continuity. Management said sales cycles shortened across several segments in the first half, a reversal from the deal elongation it described through late 2025, and lifted second-half enterprise assumptions from flat to accelerating. A third consecutive quarter of underlying ARR acceleration would validate that shift. So would further wins tied to the 365 Talents integration, which management said was running ahead of schedule and had already helped land marquee telecom and automotive customers. The third quarter is also the first heavy federal quarter with a meaningful FedRAMP pipeline, making public-sector bookings a useful read on whether that investment is maturing. Progress on Agent Hub and Enterprise Knowledge availability, plus the partner channel that now touches roughly 80% of enterprise pipeline, rounds out the scorecard. Any sign of AI credit pricing pushback from cost-conscious buyers would be worth noting.
Sentiment has swung from firmly bearish to modestly bullish, and the stock trades near $29.71, far above its 200-day average of about $20.35 and roughly 5% below its post-earnings high of $31.27. The entire trading range since the last report sits above the prior quarter's ceiling of $22.34, a sign of how much the narrative has improved. It also means the stock is no longer priced for skepticism.
The central issue is whether Docebo can show that enterprise-led reacceleration is durable while explaining how its new spending will pay off. Meeting the midpoint on revenue is table stakes. What keeps the story intact is accelerating underlying ARR, a credible monetization plan for healthcare and FDE, and an outlook that at least holds the full-year range as the AWS and Dayforce drag fades.